Medifast Analyst Ratings
Medifast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 19.05% | Stephens & Co. | → $82 | Initiates Coverage On | → Equal-Weight |
| 08/08/2023 | 16.14% | DA Davidson | $93 → $80 | Maintains | Neutral |
| 07/31/2023 | 35.02% | DA Davidson | $75 → $93 | Maintains | Neutral |
| 05/02/2023 | 3.08% | DA Davidson | $94 → $71 | Maintains | Neutral |
| 02/22/2023 | 36.47% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 53.89% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 303.6% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 117.77% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 411.03% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 395.06% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 406.68% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 473.46% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 338.44% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 284.73% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 246.98% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 197.62% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 138.1% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | 24.85% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | 20.5% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | 7.43% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 88.73% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 213.59% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月13日 | 19.05% | 斯蒂芬斯公司 | →$82 | 開始承保 | →等重 |
| 2023/08/08 | 16.14% | 達·戴維森 | $93→$80 | 維護 | 中性 |
| 07/31/2023 | 35.02% | 達·戴維森 | $75→$93 | 維護 | 中性 |
| 05/02/2023 | 3.08% | 達·戴維森 | $94→$71 | 維護 | 中性 |
| 02/22/2023 | 36.47% | 達·戴維森 | $106→$94 | 維護 | 中性 |
| 11/04/2022 | 53.89% | 達·戴維森 | $278→$106 | 評級下調 | 購買→中性 |
| 08/04/2022 | 303.6% | 達·戴維森 | $352→$278 | 維護 | 買 |
| 08/04/2022 | 117.77% | 傑富瑞 | $345→$150 | 評級下調 | 購買→Hold |
| 06/02/2022 | 411.03% | 達·戴維森 | $341→$352 | 維護 | 買 |
| 02/24/2022 | 395.06% | 達·戴維森 | $349→$341 | 維護 | 買 |
| 11/08/2021 | 406.68% | 達·戴維森 | $395→$349 | 維護 | 買 |
| 05/05/2021 | 473.46% | 達·戴維森 | $302→$395 | 維護 | 買 |
| 02/26/2021 | 338.44% | 達·戴維森 | $239→$302 | 維護 | 買 |
| 2021/01/25 | 284.73% | 傑富瑞 | $205→$265 | 升級 | 持有→購買 |
| 2021/12/01 | 246.98% | 達·戴維森 | $205→$239 | 維護 | 買 |
| 11/05/2020 | 197.62% | 達·戴維森 | $180→$205 | 升級 | 中性→購買 |
| 06/25/2020 | 138.1% | B.萊利證券 | →$164 | 開始承保 | →購買 |
| 05/06/2020 | 24.85% | 達·戴維森 | $83→$86 | 維護 | 中性 |
| 02/27/2020 | 20.5% | 達·戴維森 | $74→$83 | 維護 | 中性 |
| 2019年8月11日 | 7.43% | 達·戴維森 | $250→$74 | 評級下調 | 購買→中性 |
| 2019年07月25日 | 88.73% | 傑富瑞 | →$130 | 開始承保 | →購買 |
| 2019年02月27日 | 213.59% | 西多蒂公司 | $211→$216 | 維護 | 買 |
| 2018/08/11 | - | 西多蒂公司 | 升級 | 中性→購買 |
What is the target price for Medifast (MED)?
Medifast(MED)的目標價格是多少？
The latest price target for Medifast (NYSE: MED) was reported by Stephens & Co. on October 13, 2023. The analyst firm set a price target for $82.00 expecting MED to rise to within 12 months (a possible 19.05% upside). 6 analyst firms have reported ratings in the last year.
史蒂芬斯公司於2023年10月13日公佈了Medifast(紐約證券交易所市場代碼：MED)的最新目標價。這家分析公司將目標價定為82.00美元，預計MED將在12個月內上漲(可能上漲19.05%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Medifast (MED)?
Medifast(MED)的最新分析師評級是多少？
The latest analyst rating for Medifast (NYSE: MED) was provided by Stephens & Co., and Medifast initiated their equal-weight rating.
對Medifast(紐約證券交易所市場代碼：MED)的最新分析師評級是由Stephens&Co.提供的，Medifast啟動了他們的同等權重評級。
When is the next analyst rating going to be posted or updated for Medifast (MED)?
Medifast(MED)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Medifast的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Medifast的上一次評級是在2023年10月13日提交的，因此您應該預計下一次評級將在2024年10月13日左右提供。
Is the Analyst Rating Medifast (MED) correct?
分析師對Medifast(MED)的評級正確嗎？
While ratings are subjective and will change, the latest Medifast (MED) rating was a initiated with a price target of $0.00 to $82.00. The current price Medifast (MED) is trading at is $68.88, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Medifast(MED)評級是以0.00美元至82.00美元的目標價啟動的。Medifast(MED)目前的交易價格為68.88美元，在分析師的預測範圍內。